NCT03358966

Brief Summary

Patients with kidney disease need accurate advice on their diet. Researchers know very little about energy needs and nutritional requirements in kidney patients. Simple tools are needed to calculate calorie requirements so that good bed-side advice can be given to patients, and to allow cost-effective research. This study aimed to measur energy requirements in kidney disease using a gold-standard safe and very accurate method called the "doubly labelled water technique". The study has compared measurements with less costly measurements obtained using a device which measures oxygen content of air breathed out. The study has also measured physical activity levels with questionnaires.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2008

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2014

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2015

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

November 27, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 2, 2017

Completed
Last Updated

December 4, 2017

Status Verified

October 1, 2017

Enrollment Period

5.7 years

First QC Date

November 27, 2017

Last Update Submit

December 1, 2017

Conditions

Keywords

chronic kidney diseaseenergy expendituremetabolic rate

Outcome Measures

Primary Outcomes (1)

  • Energy expenditure using doubly labelled water

    14 days

Secondary Outcomes (3)

  • Whole body bioimpedance

    1 day

  • Resting Energy Expenditure using indirect calorimetry

    1 day

  • Stanford 7 day recall questionnaire physical activity level

    7 days

Study Arms (2)

Early to moderate CKD (stage 1-3)

40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.

Other: Doubly-labelled water techniqueOther: Resting Energy Expenditure

Advanced CKD (stage 4-5)

40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.

Other: Doubly-labelled water techniqueOther: Resting Energy Expenditure

Interventions

Advanced CKD (stage 4-5)Early to moderate CKD (stage 1-3)

Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.

Advanced CKD (stage 4-5)Early to moderate CKD (stage 1-3)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with chronic kidney disease who attended the renal clinics of the East and North Herts NHS Trust

You may qualify if:

  • CKD stages 1-5 according to the MDRD equation eGFR
  • Age \>18

You may not qualify if:

  • Abnormal thyroid stimulating hormone level or previous thyroid disorder
  • Active malignancy
  • Pregnancy
  • Intercurrent illness or infection
  • Hospital admission in month prior to enrolment
  • Surgery in 4 weeks prior to enrolment
  • HIV, Hepatitis B, Hepatitis C positive status
  • Tuberculosis in the 12 months prior to enrolment.
  • Active vasculitis or connective tissue disorder
  • Organ transplantation.
  • Treatment with immunosuppression, except low dose corticosteroids (\<10mg/day prednisolone).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Kidney DiseasesRenal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesRenal InsufficiencyChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Professor Ken Farrington

    East and North Hertfordshire NHS Trust

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 27, 2017

First Posted

December 2, 2017

Study Start

September 1, 2008

Primary Completion

May 30, 2014

Study Completion

May 30, 2015

Last Updated

December 4, 2017

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share